New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC) ...
CAMBRIDGE, MA, USA; ROTTERDAM, The Netherlands and SUZHOU, China I 8, 2024 I Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical ...
Late-Breaker Poster Presentation to occur at the 39th Annual Society for Immunotherapy of Cancer (SITC) conference on November 9th, 2024 - ...
REDMOND, WA, USA I November 8, 2024 I SystImmune, Inc (SystImmune), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational ...
“Immunotherapy and personalized therapy has transformed cancer treatment. However, there is still a dire need for new innovative therapies. We believe that AM003 — as a new class of individualized ...
SHANGHAI, China I November 8, 2024 I Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, showcased the “Preclinical Development of 7MW4811, an Mtoxin™ (MF6)-based ...
LOS ANGELES, CA, USA I November 8, 2024 I Nammi Therapeutics, Inc. (Nammi), a clinical stage immuno-oncology company with a diverse pipeline created with the Masked-Immunocytokine (MIC) and Nammisome ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback